Nasdaq Allo News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Nasdaq allo. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Nasdaq Allo Today - Breaking & Trending Today
Allogene Therapeutics, Inc. (NASDAQ:ALLO – Get Free Report)’s stock price traded down 3.6% during mid-day trading on Wednesday . The stock traded as low as $3.24 and last traded at $3.25. 110,132 shares traded hands during mid-day trading, a decline of 96% from the average session volume of 2,523,398 shares. The stock had previously closed […] ....
Aaron Wealth Advisors LLC purchased a new position in Allogene Therapeutics, Inc. (NASDAQ:ALLO – Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 10,729 shares of the company’s stock, valued at approximately $34,000. Several other hedge funds and other institutional investors have […] ....
Allogene Therapeutics, Inc. (NASDAQ:ALLO – Get Free Report)’s stock price shot up 2.2% during trading on Wednesday . The stock traded as high as $4.23 and last traded at $4.20. 1,019,834 shares were traded during trading, a decline of 61% from the average session volume of 2,615,178 shares. The stock had previously closed at $4.11. […] ....
Allogene Therapeutics, Inc. (NASDAQ:ALLO – Free Report) – Research analysts at Zacks Research lifted their Q1 2024 earnings per share estimates for Allogene Therapeutics in a report issued on Tuesday, February 6th. Zacks Research analyst S. Ganoria now expects that the company will earn ($0.48) per share for the quarter, up from their prior forecast […] ....
Allogene Therapeutics (NASDAQ:ALLO – Free Report) had its price target lowered by HC Wainwright from $12.00 to $10.00 in a report published on Friday, Benzinga reports. The firm currently has a buy rating on the stock. Other analysts have also issued reports about the company. Guggenheim lowered Allogene Therapeutics from a buy rating to a […] ....